Clinical Trials Addressing Unmet Needs of Rare Neurodegenerative Diseases (R01) Clinical Trials Required

The purpose of this Notice of Funding Opportunity (NOFO) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults.

Through the support of collaborative,


efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.
Related Programs

Food and Drug Administration_Research

Department of Health and Human Services


Agency: Department of Health and Human Services

Office: Food and Drug Administration

Estimated Funding: $900,000


Relevant Nonprofit Program Categories





Obtain Full Opportunity Text:
RFA-FD-25-001 Funding Opportunity Announcement

Additional Information of Eligibility:
See Eligibility Information on page 12 of the attached solicitation document.

Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-25-001.html

Contact:


Agency Email Description:
terrin.brown@fda.hhs.gov

Agency Email:


Date Posted:
2024-08-23

Application Due Date:


Archive Date:
2025-11-20


John Converse Townsend, a Forbes contributor, shares what can the private sector do for a social enterprise. He encourages social enterprises to reach out to corporations for help to scale up their businesses.






More Federal Domestic Assistance Programs


Wood Education and Resource Center (WERC) | Assistive Technology | Maternal and Child Health Federal Consolidated Programs | HIV Prevention Activities_Non-Governmental Organization Based | Regional Environmental Priority Projects |  Site Style by YAML | Grants.gov | Grants | Grants News | Sitemap | Privacy Policy


Edited by: Michael Saunders

© 2004-2025 Copyright Michael Saunders